Thomas John discusses a pooled analysis of data from three early-phase trials showing the intracranial efficacy of entrectinib in patients with solid tumors and central nervous system metastases (5:33).
In patients with clear cell renal cell carcinoma and untreated central nervous system metastases, intracranial response to nivolumab monotherapy is restricted to those with a limited tumor burden, suggest phase II findings.
Marginal survival gains among patients with small-cell lung cancer who receive twice- versus once-daily thoracic radiotherapy plus prophylactic cranial irradiation occur at the cost of an increased risk for brain metastases, research shows.
Neurosurgical resection of brain metastases followed by stereotactic radiation can lead to pachymeningeal seeding outside of the stereotactic radiation field, according to findings reported in JAMA Oncology.
The outcomes of patients with a first recurrence of WHO grade II or III glioma without the 1p/19q co-deletion are not improved when bevacizumab is added to the standard of care temozolomide, suggest phase II trial findings.